DTC Ads To Be Studied By FDA With Eye On Efficacy Presentations
Executive Summary
A study proposed by FDA to evaluate how benefit information is conveyed through direct to consumer advertisements could end up showing drug marketers how to describe "high" and "low" efficacy drugs
You may also be interested in...
FDA May Allow "Qualitative" Labels For Data In DTC Ads
Study of "format variations" in the brief summary of print advertisements will test different ways of presenting benefit and risk information.
Opening Product Labeling To Broader CE Data Is Proposed In Senate Bill
Drug product labels could contain an array of comparative effectiveness data beyond well-controlled clinical trials, if Sens. Jack Reed, D-R.I., and Barbara Mikulski, D-Md., get their way
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions